These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35760938)

  • 81. The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study.
    Porntharukchareon T; Chartisathian W; Navinpipat M; Samdaengpan C; Cheirsilpa K; Lueprasitsakul A; Worawichawong S; Muangsillapasart V; Pumuthaivirat P; Dechates B; Sirisreetreerux S; Siripongboonsitti T; Rangsrisaeneepitak V; Jirawattanapalin K; Tawinprai K
    Hum Vaccin Immunother; 2023 Aug; 19(2):2251850. PubMed ID: 37671943
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review.
    He YF; Ouyang J; Hu XD; Wu N; Jiang ZG; Bian N; Wang J
    World J Diabetes; 2023 Jun; 14(6):892-918. PubMed ID: 37383586
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV.
    Wang Y; Li J; Zhang W; Liu S; Miao L; Li Z; Fu A; Bao J; Huang L; Zheng L; Li E; Zhang Y; Yu J
    Front Immunol; 2023; 14():1152695. PubMed ID: 36936952
    [TBL] [Abstract][Full Text] [Related]  

  • 84. B-Cell Responses to Sars-Cov-2 mRNA Vaccines.
    Kardava L; Buckner CM; Moir S
    Pathog Immun; 2022; 7(2):93-119. PubMed ID: 36655200
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.
    Joudeh AI; Lutf AQ; Mahdi S; Tran G
    Vaccine; 2023 Jun; 41(26):3801-3812. PubMed ID: 37244811
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Immunogenicity of COVID-19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: A systematic review and meta-analysis.
    Al-Haideri M; Mohammad TAM; Darvishzadehdeldari S; Karbasi Z; Alimohammadi M; Faramarzi F; Khorasani S; Rasouli A; Tahmasebi S; Darvishi M; Akhavan-Sigari R
    Int J Rheum Dis; 2023 Jul; 26(7):1227-1234. PubMed ID: 37309305
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effectiveness of delayed second dose of AZD1222 vaccine in patients with autoimmune rheumatic disease.
    Mehta P; Paul A; Ahmed S; Cherian S; Panthak A; Benny J; Shenoy P
    Clin Rheumatol; 2022 Nov; 41(11):3537-3542. PubMed ID: 35760938
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.
    Frommert LM; Arumahandi de Silva AN; Zernicke J; Scholz V; Braun T; Jeworowski LM; Schwarz T; Tober-Lau P; Ten Hagen A; Habermann E; Kurth F; Sander LE; Corman VM; Burmester GR; Biesen R; Albach FN; Klotsche J
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597977
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Single-cell RNA sequencing to decipher the immunogenicity of ChAdOx1 nCoV-19/AZD1222 and mRNA-1273 vaccines in patients with autoimmune rheumatic diseases.
    Chen YJ; Cheng PL; Huang WN; Chen HH; Chen HW; Chen JP; Lin CT; Tang KT; Hung WT; Hsieh TY; Chen YH; Chen YM; Hsiao TH
    Front Immunol; 2022; 13():920865. PubMed ID: 35979368
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effects of the second dose of COVID-19 vaccines in patients with autoimmune rheumatic diseases with hybrid immunity.
    Menon AR; Cherian S; Paul A; Kumar K; Ahmed S; Mehta P; Musthafa S; Gayathri B; Benny L; Shenoy P
    Rheumatol Int; 2023 Mar; 43(3):449-457. PubMed ID: 36583801
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases.
    Benny L; Mehta P; Ahmed S; Paul A; Sukumaran A; Mohanan M; Vijayan A; Kaveri K; Padmaja R; Shenoy P
    Rheumatol Int; 2023 Jun; 43(6):1033-1039. PubMed ID: 37029793
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort.
    Ahmed S; Mehta P; Paul A; Anu S; Cherian S; Shenoy V; Nalianda KK; Joseph S; Poulose A; Shenoy P
    Ann Rheum Dis; 2022 Jun; 81(6):868-874. PubMed ID: 35135831
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Extended interval BNT162b2 vaccination enhances peak antibody generation.
    Parry H; Bruton R; Stephens C; Bentley C; Brown K; Amirthalingam G; Hallis B; Otter A; Zuo J; Moss P
    NPJ Vaccines; 2022 Jan; 7(1):14. PubMed ID: 35087066
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Perceived Risk of SARS-CoV-2 at the Start of the COVID-19 Pandemic and Subsequent Vaccination Attitudes in Patients With Rheumatic Diseases: A Longitudinal Analysis.
    Duculan R; Mancuso CA
    J Clin Rheumatol; 2022 Jun; 28(4):190-195. PubMed ID: 35067512
    [TBL] [Abstract][Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.